Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
---|---|---|---|---|---|---|
FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
MOREPEN LABORATORIES LTD. | 3953.77 | 80.61 | 3912.84 | 0.15 | 2,797 | 30.2 |
PANACEA BIOTEC LTD. | 1172.0 | -67.0 | 1122.5 | -1.09 | 2762 | |
Krsnaa Diagnostics Limited | 1796.13 | 195.62 | 1756.15 | 6 | 2688 | 33.5 |
Morepen Laboratories Ltd., with Security Code 500288, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
---|---|---|---|---|---|---|---|---|---|---|
Sales | 336.5 | 369.1 | 381.3 | 394.6 | 392.6 | 385.6 | 383.7 | 403.3 | 381.9 | 391.3 |
Expenses | 321.4 | 344.3 | 351.5 | 343.5 | 336.5 | 337.0 | 340.6 | 371.7 | 351.7 | 372.3 |
Operating Profit | 15.1 | 24.8 | 29.8 | 51.1 | 56.1 | 48.6 | 43.1 | 31.6 | 30.2 | 19.0 |
OPM % | 4.5% | 6.72% | 7.81% | 12.95% | 14.3% | 12.6% | 11.22% | 7.83% | 7.92% | 4.84% |
Other Income | 3.0 | 2.1 | 2.8 | 3.7 | 4.0 | 3.1 | 4.6 | 4.9 | 3.1 | 4.1 |
Interest | 0.6 | 0.3 | 0.5 | 2.0 | 0.7 | 1.0 | 1.1 | 1.3 | 3.7 | 3.8 |
Depreciation | 4.6 | 4.9 | 4.8 | 5.5 | 6.7 | 3.6 | 3.8 | 4.8 | 12.3 | 7.9 |
Profit before tax | 12.9 | 21.7 | 27.3 | 47.2 | 52.7 | 47.0 | 42.9 | 30.4 | 17.4 | 11.4 |
Tax % | -20.6% | -27% | -27.1% | -25.5% | -24.2% | -25.5% | 25.5% | -25.3% | -30.6% | 29% |
Net Profit | 10.3 | 15.9 | 19.9 | 35.2 | 40.0 | 35.1 | 31.9 | 22.7 | 11.9 | 8.1 |
EPS in Rs | 0.2 | 0.31 | 0.39 | 0.69 | 0.78 | 0.69 | 0.6 | 0.41 | 0 | 0.15 |
Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|
Sales | 348.5 | 363.7 | 401.0 | 421.8 | 444.6 | 423.1 | 455.2 | 437.7 | 452.8 | 465.9 |
Expenses | 327.9 | 348.1 | 374.9 | 388.2 | 394.0 | 375.2 | 403.6 | 393.7 | 416.6 | 423.6 |
Operating Profit | 20.5 | 15.6 | 26.1 | 33.6 | 50.6 | 47.9 | 51.6 | 44.1 | 36.1 | 42.3 |
OPM % | 5.89% | 4.28% | 6.51% | 7.96% | 11.37% | 11.33% | 11.34% | 10.07% | 7.98% | 9.08% |
Other Income | 1.2 | 3.1 | 2.4 | 3.2 | 4.1 | 4.2 | 3.4 | 5.0 | 5.3 | 4.6 |
Interest | 0.6 | 0.6 | 0.3 | 0.5 | 2.2 | 0.8 | 1.2 | 1.2 | 1.3 | 4.7 |
Depreciation | 7.2 | 7.0 | 7.7 | 7.7 | 8.4 | 9.6 | 5.7 | 1.9 | 4.9 | 16.5 |
Profit before tax | 14.0 | 11.1 | 20.5 | 28.7 | 44.0 | 41.7 | 48.2 | 46.0 | 35.2 | 25.8 |
Tax % | -35.8% | -26% | -28.7% | -25.9% | -27.3% | -31.9% | 24.9% | -24.3% | 24.2% | -21% |
Net Profit | 9.0 | 8.2 | 14.6 | 21.3 | 32.0 | 28.3 | 36.2 | 34.8 | 26.7 | 20.3 |
EPS in Rs | 0.16 | 0.16 | 0.29 | 0.42 | 0.63 | 0.54 | 0.71 | 0.65 | 0.49 | 0 |
Compounded Sales Growth | |
---|---|
10 Years: | 15% |
5 Years: | 14% |
3 Years: | 2% |
TTM: | 1% |
Compounded Profit Growth | |
---|---|
10 Years: | 68% |
5 Years: | 26% |
3 Years: | 0% |
TTM: | -8% |
Stock Price CAGR | |
---|---|
10 Years: | 18% |
5 Years: | 34% |
3 Years: | 19% |
1 Year: | 36% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 16% |
3 Years: | 5% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | 49% |
5 Years: | 29% |
3 Years: | 5% |
TTM: | 23% |
Stock Price CAGR | |
---|---|
10 Years: | 18% |
5 Years: | 34% |
3 Years: | 19% |
1 Year: | 36% |
Recent Bets
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
---|
Period | SMA Value | Status |
---|
Period | EMA Value | Status |
---|
Indicator | Value |
---|